Tag - ABUS

Markets

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

December 17, 2020

Developments

Arbutus and Roivant launch Genevant Sciences to develop RNA therapeutics

Arbutus Biopharma (NASDAQ:ABUS) and closely-held Roivant Sciences of Switzerland agreed to launch Genevant Sciences, a jointly-owned company focused on the discovery, development, and commercialization of a broad range...

April 11, 2018

Feature

Arbutus taking multi-faceted approach to HBV

By Len Zehr Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with...

January 17, 2017

Tag - ABUS

HCW starts Arbutus Biopharma at buy; PT $10

Arbutus and Roivant launch Genevant Sciences to develop RNA therapeutics

Arbutus taking multi-faceted approach to HBV

General

More